CSL Shares Drop to Decade Low as Oversold Conditions Fail to Stem Tide

CSL shares (ASX: CSL) head into the new week at A$119.88, testing the A$120 support level before retreating, as the biotechnology giant’s prolonged sell-off shows no signs of abating despite extreme technical oversold readings that historically signal a potential reversal.

The CSL share price touched a new intraday low of A$119.61 early Friday, capping a brutal week that saw shares decline another 3.97 per cent. Year-to-date, CSL has now plummeted 30.29 per cent, with the 12-month performance showing an even more alarming drop of 50 per cent from highs above A$200. The company now holds the dubious distinction of being the most oversold stock on the ASX among companies with market capitalisation exceeding A$100 million, with the Relative Strength Index registering 22.43 on the daily chart and 21.01 on the weekly timeframe, both well below the 30 threshold that technical analysts typically associate with oversold territory.

Markets have continued to pressure the shares despite several factors that would normally provide support. CSL has maintained an aggressive on-market buy-back programme, with recent ASX announcements showing cumulative purchases exceeding 6 million shares under the current programme. Daily repurchase updates from late April and early May 2026 reveal the company buying tens of thousands of shares on individual trading days, including approximately 55,000 shares on 1 May alone, as management seeks to deploy capital at what the board evidently views as attractive valuations.

Yet the buy-back has failed to stem the decline, raising questions about whether fundamental concerns are simply too significant for capital management initiatives to offset. The persistent weakness follows a series of setbacks that have fundamentally altered markets’ perception of CSL’s growth trajectory and defensive qualities.

The company’s most recent half-year result for HY26, reported in February, showed underlying net profit after tax and amortisation falling by mid-single digits compared to the prior comparable period. The decline reflected weaker plasma collection volumes and margin pressure across the core immunoglobulin business, which has historically been CSL’s profit engine. Slower-than-expected plasma donor recruitment, coupled with ongoing cost inflation in donor compensation, logistics, and manufacturing, has compressed margins and forced analysts to reassess the company’s long-term earnings power.

While extreme oversold conditions can precede powerful rebounds, they are not in themselves sufficient to trigger a reversal without an accompanying improvement in fundamentals or sentiment. The fact that CSL has remained oversold for an extended period, with RSI readings in the low 20s persisting across multiple timeframes, suggests that forced selling and systematic de-risking by institutional investors may still be underway.

Macro factors have also weighed on the stock, with CSL’s characteristics as a long-duration growth asset making it particularly vulnerable to higher real yields and a rotation away from defensive healthcare names into cheaper cyclicals and value stocks. The broader sector backdrop for global large-cap healthcare has been challenging, with multiple compression affecting premium-rated names across developed markets.

After another bruising week, CSL bulls will be looking for a floor to form soon, yet trying to catch that bottom so far has been akin to the old falling knife. A period of consolidation at this stage would be welcome relief, but let’s see what the upcoming week has in store.